Company intelligence / Profile preview
New England Cell Therapeutics
New Haven, Connecticut, United Statesnecelltx.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
New England Cell Therapeutics is a development-stage biotech company focused on delivering mesenchymal stem cell therapies to treat a range of injuries and illnesses. Its lead program, STR04, is in Phase 2 clinical trials for Amyotrophic Lateral Sclerosis (ALS), with the first trial set to start recruiting in April 2025. The company’s research also spans other nervous system and metabolic diseases. No published clinical results are available as of April 2025.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Mesenchymal stem cell therapyStem cell replacements
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on New England Cell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New England Cell Therapeutics.